08048035996
ELEFTHA 375MG Injection wholesale and global supplier from India to Australia | Phoenix Exim.

1. General Information

ELEFTHA 375MG Injection is an anti-cancer medicine containing trastuzumab 375 mg. It belongs to the monoclonal-antibody class of targeted cancer therapies and is primarily used for certain HER2-positive cancers, particularly breast cancer and some gastric or gastroesophageal-junction cancers. It is marketed in India by Intas Pharmaceuticals Ltd.

Phoenix Exim is a medicine exporter from Nagpur, India, supplying pharmaceutical products for international markets including the USA, UK, Australia, Singapore, Canada, South Korea, and UAE, subject to applicable prescription, import, and regulatory requirements.

2. Product Information

  • Brand: ELEFTHA 375MG Injection
  • Active Ingredient: Trastuzumab
  • Strength: 375 mg
  • Dosage Form: Lyophilized powder for intravenous infusion
  • Therapeutic Class: Targeted anti-cancer / monoclonal antibody
  • Manufacturer/Marketer: Intas Pharmaceuticals Ltd.
  • Route: Intravenous infusion
  • Prescription: Required
  • Storage: Follow the manufacturer's product label and approved prescribing information; trastuzumab products generally require controlled refrigerated storage.

3. Uses of ELEFTHA 375MG Injection

ELEFTHA 375MG Injection may be prescribed for cancers in which tumor cells overexpress HER2 (human epidermal growth factor receptor 2), including:

  • HER2-positive breast cancer
  • Certain HER2-positive metastatic breast cancers
  • HER2-positive gastric cancer
  • HER2-positive gastroesophageal-junction adenocarcinoma

The exact indication, combination with other medicines, and treatment schedule depend on the patient's cancer type, stage, HER2 status, and treatment protocol.

4. Benefits of This Medicine

When appropriately prescribed for HER2-positive cancer, trastuzumab can:

  • Specifically target HER2-positive cancer cells.
  • Help inhibit HER2-mediated cancer-cell growth.
  • Slow disease progression in appropriate patients.
  • Be used alongside other anti-cancer treatments when clinically indicated.
  • Provide targeted treatment rather than acting through a nonspecific mechanism alone.

The expected benefit varies significantly between patients and depends on the cancer diagnosis and treatment regimen.

5. Side Effects

ELEFTHA 375MG Injection can cause side effects. Some reactions can occur during or shortly after infusion, while others may develop during treatment.

Reported or clinically important adverse effects can include:

  • Infusion-related reactions
  • Fever and chills
  • Headache
  • Nausea or vomiting
  • Diarrhea
  • Fatigue
  • Rash
  • Cough
  • Infection
  • Swelling
  • Injection/infusion-site reactions
  • Changes in heart function
  • Lung-related complications

Serious reactions such as significant breathing difficulty, severe infusion reactions, or symptoms suggesting heart problems require prompt medical attention.

6. Common Side Effects

Commonly reported effects may include:

  1. Chills
  2. Fever
  3. Headache
  4. Nausea
  5. Vomiting
  6. Diarrhea
  7. Fatigue
  8. Cough
  9. Rash
  10. Infusion-related reactions

Not every patient experiences these effects, and their severity can vary.

7. How to Use ELEFTHA 375MG Injection

ELEFTHA 375MG is not intended for self-administration.

  • It is administered by a qualified healthcare professional.
  • It is given by intravenous infusion after appropriate preparation.
  • The dosage and frequency are determined by the oncologist.
  • Treatment may be given alone or together with other anti-cancer medicines depending on the clinical protocol.
  • Patients should follow the prescribed treatment schedule and should not change or discontinue therapy without consulting their oncologist.

8. How This Medicine Works

Trastuzumab is a monoclonal antibody that targets the HER2 protein found on the surface of certain cancer cells.

By binding to HER2, trastuzumab interferes with HER2-related signaling that can promote cancer-cell growth. It can therefore help inhibit the growth and survival of HER2-positive cancer cells and may also support immune-mediated destruction of targeted cells.

9. Safety Advice

  • Prescription use: Use only under specialist medical supervision.
  • Heart conditions: Tell your doctor about any existing or previous heart problems because trastuzumab can affect cardiac function.
  • Lung problems: Inform your doctor about existing breathing or lung conditions.
  • Pregnancy: Trastuzumab can cause fetal harm. Inform your healthcare provider if you are pregnant, planning pregnancy, or could become pregnant.
  • Breastfeeding: Discuss breastfeeding with your doctor before starting treatment.
  • Allergies: Inform the healthcare team about previous reactions to trastuzumab or any formulation ingredients.
  • Monitoring: Your oncology team may monitor heart function and other laboratory parameters during treatment.
  • Drug interactions: Tell your doctor about all prescription medicines, over-the-counter medicines, supplements, and other cancer treatments you are taking.
  • Storage: Maintain the manufacturer's recommended cold-chain/storage conditions and protect the product as directed.

10. Frequently Asked Questions (FAQs)

Q1. What is ELEFTHA 375MG Injection used for?
It is a trastuzumab-based targeted cancer medicine used for certain HER2-positive cancers, including breast cancer and some gastric/gastroesophageal-junction cancers.

Q2. What is the active ingredient in ELEFTHA 375MG?
The active ingredient is trastuzumab 375 mg.

Q3. How is ELEFTHA 375MG administered?
It is administered intravenously by a trained healthcare professional.

Q4. Can ELEFTHA 375MG be self-administered?
No. It should be administered under appropriate medical supervision.

Q5. Does ELEFTHA 375MG work for all breast cancers?
No. It is intended for appropriately diagnosed HER2-positive cancers; HER2 testing and specialist assessment are important before treatment.

Q6. Can ELEFTHA 375MG affect the heart?
Yes. Trastuzumab can cause cardiac dysfunction in some patients, so appropriate cardiac monitoring may be required.

Q7. What are some common side effects?
Chills, fever, headache, nausea, diarrhea, fatigue, cough, and infusion-related reactions may occur.

Q8. Does ELEFTHA 375MG require a prescription?
Yes. It is a prescription anti-cancer medicine and should be used under specialist supervision.

11. Substitutes for ELEFTHA 375MG Injection

Possible alternatives may include other trastuzumab 375 mg products, depending on availability and the treating physician's decision. Examples listed by Indian medicine references include Trasturel 375MG Injection and Vivitra 375MG Injection.

A substitute should not be selected solely on the basis of the brand name or price. The oncologist or pharmacist should confirm that the alternative contains the appropriate active ingredient, strength, formulation, and is suitable for the patient's treatment protocol.

12. SEO Keywords

Primary keywords:

  • ELEFTHA 375MG Injection
  • Eleftha 375 mg Injection exporter
  • Eleftha 375mg supplier from India
  • Eleftha 375mg pharmaceutical exporter
  • Trastuzumab 375mg Injection exporter
  • Trastuzumab 375mg supplier India
  • Eleftha 375mg wholesale supplier
  • Eleftha 375mg medicine exporter
  • Eleftha 375mg cancer injection
  • HER2 positive cancer medicine exporter

Long-tail B2B keywords:

  • Buy Eleftha 375mg Injection from India
  • Eleftha 375mg Injection wholesale supplier India
  • Eleftha 375mg Injection pharmaceutical exporter from Nagpur
  • Trastuzumab 375mg Injection exporter from India
  • Genuine Eleftha 375mg Injection supplier
  • Eleftha 375mg Injection international medicine supplier
  • Eleftha 375mg Injection exporter to USA
  • Eleftha 375mg Injection exporter to UK
  • Eleftha 375mg Injection exporter to Australia
  • Eleftha 375mg Injection exporter to Singapore
  • Eleftha 375mg Injection exporter to Canada
  • Eleftha 375mg Injection exporter to South Korea
  • Eleftha 375mg Injection exporter to UAE
  • HER2 targeted therapy medicine supplier from India
  • Trastuzumab oncology medicine exporter India
Aug 22nd, 2026 1:02 PM

Keywords